HealthQuill Alzheimer's Disease
Alzheimer's disease has an initial silent and slow phase before the second stage of a destructive accumulation of plaques, tangles and other symptoms occurs, a brain-mapping study funded by the National Institutes of Health finds.
Health Uncategorized

EU regulators reverse course, approve Alzheimer’s drug Leqembi

HQ Team November 19, 2024: The European Medicines Agency (EMA) granted conditional approval for lecanemab, for the treatment of early Alzheimer’s disease in.

Read More
Alzheimer's disease has an initial silent and slow phase before the second stage of a destructive accumulation of plaques, tangles and other symptoms occurs, a brain-mapping study funded by the National Institutes of Health finds.
Drugs Health Medical

Alzheimer’s disease slowly enters the brain in a stealth mode

Alzheimer's disease has an initial silent and slow phase before the second stage of a destructive accumulation of plaques, tangles and other symptoms.

Read More
Sage Therapeutics Inc.’s experimental drug failed to meet its main goal of treating mild dementia due to Alzheimer's disease and the US, Cambridge-headquartered company has halted its trials.
Drugs Health Pharma

Sage Therapeutics halts trials of experimental drug to treat dementia

Sage Therapeutics Inc.’s experimental drug failed to meet its main goal of treating mild dementia due to Alzheimer's disease and the US, Cambridge-headquartered.

Read More
Eli Lilly and Company will invest one billion dollars to expand its facility in Ireland to increase its production of drugs to treat Alzheimer’s disease, diabetes and obesity, according to a company statement.
Drugs Health Pharma

Eli Lilly to invest $1b in Irish facility to make Alzheimer’s, obesity drugs

Eli Lilly and Company will invest one billion dollars to expand its facility in Ireland to increase its production of drugs to treat.

Read More
Environmental micro and nanoplastics (MNPs) accumulate in the human brain and total mass concentrations have risen by more than 50% in the past eight years, a study reveals.
Drugs Health Pharma

‘Shard-like plastic remnants’ of varying sizes amass in the brain: UNM

Environmental micro and nanoplastics (MNPs) accumulate in the human brain and total mass concentrations have risen by more than 50% in the past.

Read More
An eye scan can spot early signs of Alzheimer’s disease in the retina or the small blood vessels in the back of the eye in seconds before it affects the brain, two studies reveal.
Drugs Health Pharma

Quick eye scan can detect Alzheimer’s disease in seconds: Scientists

An eye scan can spot early signs of Alzheimer’s disease in the retina or the small blood vessels in the back of the.

Read More
Intensive diet and lifestyle changes may forestall a cognitive decline in Alzheimer’s disease and make progress for patients during early stages, a study finds.
Drugs Health Pharma

Diet, exercise, socialisation may help in early stage Alzheimer’s disease

Intensive diet and lifestyle changes may forestall a cognitive decline in Alzheimer’s disease and make progress for patients during early stages, a study.

Read More
The FDA has issued revised draft guidance for early treatment of Alzheimer’s disease with drugmakers told to focus on medicines that are likely to predict a clinical benefit.
Drugs Health Pharma

FDA issues revised drug guidelines for early Alzheimer’s disease

HQ Team March 12, 2024: The FDA has issued revised draft guidance for early treatment of Alzheimer’s disease with drugmakers told to focus.

Read More
Scientists have discovered five known cases of possible medically acquired Alzheimer’s disease after the patients have undergone previous treatments.
Drugs Health Pharma

Researchers find five cases of medically-acquired Alzheimer’s in UK

HQ Team February 12, 2024: Scientists have discovered five known cases of possible medically acquired Alzheimer’s disease after the patients have undergone previous.

Read More
Biogen, a US-based biotechnology company, will discontinue the development and commercialisation of its Alzheimer’s treatment and terminate its post-approval study as it failed to rope in a partner to cut costs of obtaining standard regulatory approval.
Drugs Health Pharma

Biogen abandons Alzheimer’s drug Aduhelm to focus on Leqembi

Biogen, a US-based biotechnology company, will discontinue the development and commercialisation of its Alzheimer’s treatment and terminate its post-approval study as it failed.

Read More